|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
273,070,000 |
Market
Cap: |
1.87(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$5.09 - $15.52 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, in vivo validation capabilities and a cross-functional team to discover medicines. Co.'s potential medicines include: REC-994 for the treatment of cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 for the treatment of familial adenomatous polyposis; REC-3599 for the treatment of GM2 gangliosidosis; REC-3964 for the treatment of C. difficile colitis; REC-64917 for neural or systemic inflammation; and multiple simultaneous programs in fibrosis developing with Bayer AG.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
1,693,990 |
Total Buy Value |
$0 |
$0 |
$0 |
$12,897,789 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
27 |
Total Shares Sold |
366,682 |
934,542 |
1,871,955 |
3,338,528 |
Total Sell Value |
$2,558,035 |
$7,544,746 |
$16,254,185 |
$30,762,522 |
Total People Sold |
4 |
4 |
7 |
8 |
Total Sell Transactions |
21 |
44 |
89 |
167 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Secora Michael |
Chief Financial Officer |
|
2024-01-16 |
4 |
AS |
$10.45 |
$261,160 |
D/D |
(25,000) |
968,514 |
|
-15% |
|
Secora Michael |
Chief Financial Officer |
|
2024-01-16 |
4 |
OE |
$2.22 |
$83,250 |
D/D |
37,500 |
993,514 |
|
- |
|
Virani Shafique |
Chief Business Officer |
|
2024-01-16 |
4 |
AS |
$10.93 |
$196,740 |
D/D |
(18,000) |
136,748 |
|
-15% |
|
Virani Shafique |
Chief Business Officer |
|
2024-01-16 |
4 |
OE |
$2.22 |
$39,960 |
D/D |
18,000 |
154,748 |
|
- |
|
Li Dean Y |
Director |
|
2024-01-09 |
4 |
AS |
$13.65 |
$396,214 |
I/I |
(29,000) |
421,000 |
|
-27% |
|
Borgeson Blake |
Director |
|
2024-01-09 |
4 |
AS |
$13.21 |
$273,202 |
D/D |
(20,054) |
7,344,418 |
|
-27% |
|
Gibson Christopher |
Chief Executive Officer |
|
2024-01-03 |
4 |
AS |
$9.49 |
$237,763 |
I/I |
(25,000) |
0 |
|
4% |
|
Gibson Christopher |
Chief Executive Officer |
|
2024-01-03 |
4 |
A |
$0.00 |
$0 |
I/I |
25,000 |
1,000 |
|
- |
|
Gibson Christopher |
Chief Executive Officer |
|
2024-01-03 |
4 |
AS |
$9.49 |
$292,804 |
D/D |
(30,853) |
791,725 |
|
4% |
|
Gibson Christopher |
Chief Executive Officer |
|
2024-01-03 |
4 |
OE |
$2.48 |
$77,500 |
D/D |
31,250 |
822,578 |
|
- |
|
Gibson Christopher |
Chief Executive Officer |
|
2024-01-03 |
4 |
GD |
$0.00 |
$0 |
D/D |
10,000 |
791,328 |
|
- |
|
Gibson Christopher |
Chief Executive Officer |
|
2024-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
801,328 |
|
- |
|
Li Dean Y |
Director |
|
2024-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
1,203 |
1,327,618 |
|
- |
|
Chavez R Martin Phd |
Director |
|
2024-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
1,900 |
58,077 |
|
- |
|
Dar Zavain |
Director |
|
2024-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
1,393 |
55,216 |
|
- |
|
Larson Tina Marriott |
President and COO |
|
2023-12-28 |
4 |
AS |
$10.58 |
$84,654 |
D/D |
(8,000) |
414,548 |
|
-19% |
|
Larson Tina Marriott |
President and COO |
|
2023-12-28 |
4 |
OE |
$1.06 |
$8,480 |
D/D |
8,000 |
422,548 |
|
- |
|
Borgeson Blake |
Director |
|
2023-12-26 |
4 |
AS |
$10.63 |
$213,144 |
D/D |
(20,054) |
7,364,472 |
|
-19% |
|
Virani Shafique |
Chief Business Officer |
|
2023-12-15 |
4 |
AS |
$9.60 |
$172,800 |
D/D |
(18,000) |
136,748 |
|
-15% |
|
Virani Shafique |
Chief Business Officer |
|
2023-12-15 |
4 |
OE |
$2.22 |
$39,960 |
D/D |
18,000 |
154,748 |
|
- |
|
Dar Zavain |
Director |
|
2023-12-14 |
4 |
AS |
$9.00 |
$181,269 |
D/D |
(20,141) |
53,823 |
|
-15% |
|
Secora Michael |
Chief Financial Officer |
|
2023-12-13 |
4 |
AS |
$7.59 |
$189,770 |
D/D |
(25,000) |
956,014 |
|
-6% |
|
Secora Michael |
Chief Financial Officer |
|
2023-12-13 |
4 |
OE |
$2.22 |
$83,250 |
D/D |
37,500 |
981,014 |
|
- |
|
Borgeson Blake |
Director |
|
2023-12-12 |
4 |
AS |
$7.40 |
$84,693 |
D/D |
(11,447) |
7,384,526 |
|
7% |
|
Secora Michael |
Chief Financial Officer |
|
2023-12-12 |
4 |
AS |
$7.39 |
$184,868 |
D/D |
(25,000) |
943,514 |
|
7% |
|
628 Records found
|
|
Page 4 of 26 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|